Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amgen Launches Evenity For High-Risk Osteoporosis At $21,900 List Price

Apr 16 2019

• By Mandy Jackson

The four stages of osteoporosis - illustration - Illustration — Amgen/UCB's Evenity rebuilds bone in osteoporosis. • Source: Shutterstock

Related Content

Japan Approvals Include World Firsts For Romosozumab, Spinal Injury Cell Therapy

Jan 17 2019

Evenity Likely Headed For Approval With Amgen's Proposed Indication, But Postmarketing Requirements Remain Unclear

Jan 17 2019

ARCH CV Signal Scuppers Blockbuster Hopes For Amgen/UCB's Evenity

May 22 2017

Radius Prices Osteoporosis 'Blockbuster' Tymlos To Compete, Grow Market

May 02 2017

US FDA Sends Amgen/UCB Evenity Back With BRIDGE Request

Jul 17 2017

Related Companies

Amgen, Inc.

UCB S.A.

Radius Health, Inc.

Eli Lilly and Company

Additional Topics

Launches Pricing Strategies Market Access Reimbursement Drug Safety Commercial BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.